Literature DB >> 30136421

Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma.

Ryan A Hlady1, Aishwarya Sathyanarayan1, Joyce J Thompson1, Dan Zhou1, Qunfeng Wu2, Kien Pham2, Jeong-Heon Lee3, Chen Liu2, Keith D Robertson1.   

Abstract

Disruption of epigenetic mechanisms has been intimately linked to the etiology of human cancer. Understanding how these epigenetic mechanisms (including DNA methylation [5mC], hydroxymethylation [5hmC], and histone post-translational modifications) work in concert to drive cancer initiation and progression remains unknown. Hepatocellular carcinoma (HCC) is increasing in frequency in Western countries but lacks efficacious treatments. The epigenome of HCC remains understudied. To better understand the epigenetic underpinnings of HCC, we performed a genome-wide assessment of 5mC, 5hmC, four histone modifications linked to promoter/enhancer function (H3K4me1, H3K27ac, H3K4me3, and H3K27me3), and transcription across normal, cirrhotic, and HCC liver tissue. Implementation of bioinformatic strategies integrated these epigenetic marks with each other and with transcription to provide a comprehensive epigenetic profile of how and when the liver epigenome is perturbed during progression to HCC. Our data demonstrate significant deregulation of epigenetic regulators combined with disruptions in the epigenome hallmarked by profound loss of 5hmC, locus-specific gains in 5mC and 5hmC, and markedly altered histone modification profiles, particularly remodeling of enhancers. Data integration demonstrates that these marks collaborate to influence transcription (e.g., hyper-5hmC in HCC-gained active enhancers is linked to elevated expression) of genes regulating HCC proliferation. Two such putative epigenetic driver loci identified through our integrative approach, COMT and FMO3, increase apoptosis and decrease cell viability in liver-derived cancer cell lines when ectopically re-expressed.
Conclusion: Altogether, integration of multiple epigenetic parameters is a powerful tool for identifying epigenetically regulated drivers of HCC and elucidating how epigenome deregulation contributes to liver disease and HCC.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 30136421      PMCID: PMC6351162          DOI: 10.1002/hep.30211

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  39 in total

Review 1.  A decade of exploring the cancer epigenome - biological and translational implications.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

2.  A clustering approach for identification of enriched domains from histone modification ChIP-Seq data.

Authors:  Chongzhi Zang; Dustin E Schones; Chen Zeng; Kairong Cui; Keji Zhao; Weiqun Peng
Journal:  Bioinformatics       Date:  2009-06-08       Impact factor: 6.937

3.  Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.

Authors:  Neal D Freedman; Jiyoung Ahn; Lifang Hou; Jolanta Lissowska; Witold Zatonski; Meredith Yeager; Stephen J Chanock; Wong Ho Chow; Christian C Abnet
Journal:  Carcinogenesis       Date:  2008-11-17       Impact factor: 4.944

4.  Circos: an information aesthetic for comparative genomics.

Authors:  Martin Krzywinski; Jacqueline Schein; Inanç Birol; Joseph Connors; Randy Gascoyne; Doug Horsman; Steven J Jones; Marco A Marra
Journal:  Genome Res       Date:  2009-06-18       Impact factor: 9.043

5.  Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females.

Authors:  Pen-Hui Yin; Hsin-Chen Lee; Gar-Yang Chau; Tsung-Yun Liu; Hsiu-Chih Liu; Wing-Yiu Lui; Chin-Wen Chi
Journal:  Cancer Lett       Date:  2004-08-30       Impact factor: 8.679

Review 6.  Molecular mechanisms of alcohol-mediated carcinogenesis.

Authors:  Helmut K Seitz; Felix Stickel
Journal:  Nat Rev Cancer       Date:  2007-08       Impact factor: 60.716

7.  Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival.

Authors:  Ji-Rong Long; Qiuyin Cai; Xiao-Ou Shu; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Pharmacogenet Genomics       Date:  2007-05       Impact factor: 2.089

8.  DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation.

Authors:  Bong-Kyeong Oh; Haeryoung Kim; Hye-Jung Park; Yhong-Hee Shim; Jinsub Choi; Chanil Park; Young Nyun Park
Journal:  Int J Mol Med       Date:  2007-07       Impact factor: 4.101

9.  Mapping and analysis of chromatin state dynamics in nine human cell types.

Authors:  Jason Ernst; Pouya Kheradpour; Tarjei S Mikkelsen; Noam Shoresh; Lucas D Ward; Charles B Epstein; Xiaolan Zhang; Li Wang; Robbyn Issner; Michael Coyne; Manching Ku; Timothy Durham; Manolis Kellis; Bradley E Bernstein
Journal:  Nature       Date:  2011-03-23       Impact factor: 49.962

10.  Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis.

Authors:  Alexander Meissner; Andreas Gnirke; George W Bell; Bernard Ramsahoye; Eric S Lander; Rudolf Jaenisch
Journal:  Nucleic Acids Res       Date:  2005-10-13       Impact factor: 16.971

View more
  27 in total

1.  Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance.

Authors:  Ryan A Hlady; Xia Zhao; Louis Y El Khoury; Aesis Luna; Kien Pham; Qunfeng Wu; Jeong-Heon Lee; Nikolaos T Pyrsopoulos; Chen Liu; Keith D Robertson
Journal:  Hepatology       Date:  2021-12-15       Impact factor: 17.298

2.  Accurate and highly interpretable prediction of gene expression from histone modifications.

Authors:  Fabrizio Frasca; Matteo Matteucci; Michele Leone; Marco J Morelli; Marco Masseroli
Journal:  BMC Bioinformatics       Date:  2022-04-26       Impact factor: 3.307

3.  Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2.

Authors:  Dana Lau-Corona; Woo Kyun Bae; Lothar Hennighausen; David J Waxman
Journal:  PLoS Genet       Date:  2020-05-19       Impact factor: 5.917

4.  Dihydroartemisinin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cell by Upregulating Tumor Necrosis Factor via JNK/NF-κB Pathways.

Authors:  Long Wu; Yanlei Cheng; Junjian Deng; Weiping Tao; Junjie Ye
Journal:  Evid Based Complement Alternat Med       Date:  2019-08-25       Impact factor: 2.629

Review 5.  From Genotype to Phenotype: Through Chromatin.

Authors:  Julia Romanowska; Anagha Joshi
Journal:  Genes (Basel)       Date:  2019-01-23       Impact factor: 4.096

6.  A four-methylated mRNA signature-based risk score system predicts survival in patients with hepatocellular carcinoma.

Authors:  Yu Wang; Zhiping Ruan; Sizhe Yu; Tao Tian; Xuan Liang; Li Jing; Wenyuan Li; Xiao Wang; Lcl Xiang; F X Claret; Kejun Nan; Hui Guo
Journal:  Aging (Albany NY)       Date:  2019-01-10       Impact factor: 5.682

7.  Comprehensive epigenetic analyses reveal master regulators driving lung metastasis of breast cancer.

Authors:  Kening Li; Congling Xu; Yuxin Du; Muhammad Junaid; Aman-Chandra Kaushik; Dong-Qing Wei
Journal:  J Cell Mol Med       Date:  2019-06-19       Impact factor: 5.310

8.  Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA.

Authors:  Ryan A Hlady; Xia Zhao; Xiaoyu Pan; Ju Dong Yang; Fowsiyo Ahmed; Samuel O Antwi; Nasra H Giama; Tushar Patel; Lewis R Roberts; Chen Liu; Keith D Robertson
Journal:  Theranostics       Date:  2019-09-25       Impact factor: 11.556

Review 9.  Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?

Authors:  Tianmin Xu; Haoyue Gao
Journal:  Hum Genomics       Date:  2020-05-06       Impact factor: 4.639

10.  Identification of hub genes in hepatocellular carcinoma using integrated bioinformatic analysis.

Authors:  Shengni Hua; Zhonghua Ji; Yingyao Quan; Meixiao Zhan; Hao Wang; Wei Li; Yong Li; Xu He; Ligong Lu
Journal:  Aging (Albany NY)       Date:  2020-03-26       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.